Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapy
US11891614B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 17, 2020 |
| Grant date | Feb 6, 2024 |
| Priority date | — |
| Expiry date | May 17, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.